StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $1.31 | $1.28 | -2.29% | 0.1M |
| 05-15 | $1.27 | $1.25 | -1.57% | 0.0M |
| 05-18 | $1.27 | $1.17 | -7.87% | 0.1M |
| 05-19 | $1.16 | $1.15 | -0.86% | 0.1M |
| 05-20 | $1.18 | $1.17 | -0.85% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $90.00K | $90.00K | $81.00K | $1.03M |
Operating Income | $-36.25M | $-29.83M | $-51.92M | $-34.10M |
Net Income | $-33.89M | $-27.95M | $-48.82M | $-33.02M |
EPS (Diluted) | $-1.09 | $-0.90 | $-1.83 | $-1.37 |
Total Assets | $51.77M | $56.15M | $81.44M | $114.19M |
Total Liabilities | $43.94M | $42.37M | $45.07M | $47.71M |
Cash & Equivalents | $48.00M | $53.39M | $76.68M | $108.91M |
Free Cash Flow OCF − CapEx | $-24.68M | Not available | $-47.49M | $8.28M |
Shares Outstanding | 31.20M | 31.20M | 27.63M | 25.67M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.